Eszopiclone ingestions reported to Texas poison control centers, 2005-2006

Human and Experimental Toxicology

Volumn 26, Issue 10, 2007, Pages 795-800

  Forrester, Mathias B ^a  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

Adverse exposures; Eszopiclone; Management; Poison control centers

Indexed keywords

ALCOHOL; ALPRAZOLAM; CLONAZEPAM; ESZOPICLONE; QUETIAPINE; ZOLPIDEM;

ADOLESCENT; ADULT; AGITATION; ARTICLE; ATAXIA; CHILD; CONFUSION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG INTOXICATION; FEMALE; HEALTH CARE FACILITY; HUMAN; HYPERGLYCEMIA; IRRITABILITY; LACRIMATION; LETHARGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; POISON CENTER; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SIDE EFFECT; SLURRED SPEECH; SUICIDE; TACHYCARDIA; THROAT IRRITATION; UNITED STATES; VERTIGO; VOMITING;

AZABICYCLO COMPOUNDS; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; POISON CONTROL CENTERS; POISONING; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 36849011525     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327107084045     Document Type: Article

References (23)

1. Prescribing information. Lunesta™ (eszopiclone) tablets. Sepracor, Inc., 2004; 1-25.
2. Georgiev V. (S)-Zopiclone sepracor. Curr Opin Investig Drugs 2001; 2: 271-73.
3. Luddens H, Korpi ER. Biological function of GABAA/benzodiazepine receptor heterogeneity. J Psychiatr Res 1995; 29: 77-94.
4. Leese P, Maier G. Eszopiclone: pharmacokinetic (PK) and pharmacodynamic (PD) effects of a novel anti-insomnia agent after daytime administration in healthy subjects. Sleep 2002; 25: A45.
5. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of zopiclone into schedule IV. Final rule. Fed Register 2005; 70: 16935-7.
6. Anonymous. Hypnotic - eszopiclone. Manuf Chem 2004; 75: 21.
7. Rosenberg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005; 6: 15-22.
8. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6: 487-95.
9. Scharf M, Erman M, Rosenberg R, Seiden D, McCall WV, Amato D, Wessel TC. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005; 28: 720-7.
10. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20: 1979-91.
11. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26: 793-9.
12. Lovett B, Watts D, Grossman M. Prolonged coma after eszopiclone overdose. Am J Emerg Med 2007; 25: 735.e5-6.
13. Miller AH, Bruggman AR, Miller MM. Lunesta overdose: ST-elevation coronary vasospasm, troponemia, and ventricular fibrillation arrest. Am J Emerg Med 2006; 24: 741-6.
14. Boniface PJ, Russell SG. Two cases of fatal zopiclone overdose. J Anal Toxicol 1996; 20: 131-3.
15. Reith DM, Fountain J, McDowell R, Tilyard M. Comparison of the fatal toxicity index of zopiclone with benzodiazepines. J Toxicol Clin Toxicol 2003; 41: 975-80.
16. Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. 2005 Annual report of the American association of poison control centers' national poisoning and exposure database. Clin Toxicol 2006; 44: 803-932.
17. Caravati EM, Erdman AR, Christianson G et al. Ethylene glycol exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2005; 43: 327-45.
18. Manoguerra AS, Erdman AR, Booze LL et al. Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2005; 43: 553-70.
19. Olson KR, Erdman AR, Woolf AD et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2005; 43: 797-822.
20. Wax PM, Erdman AR, Chyka PA et al. Beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2005; 43: 131-46.
21. Dart RC, Erdman AR, Olson KR et al. American association of poison control centers. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2006; 44: 1-18.
22. Manoguerra AS, Erdman AR, Wax PM et al. American association of poison control centers. Camphor poisoning: an evidence-based practice guideline for out-of-hospital management. Clin Toxicol 2006; 44: 357-70.
23. Scharman EJ, Erdman AR, Wax PM et al. Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2006; 44: 205-23.